ClinicalTrials.gg
Drug

3-Iodobenzylguanidine clinical trials

Also written 131I-MIBG.

studies test it
14
open now
2
in phase 3
1
first study started
2001

How each study uses 3-Iodobenzylguanidine is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the 3-Iodobenzylguanidine studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Other names

131I-MIBG
5
MIBG
2
I-131 Metaiodobenzylguanidine
1
iobenguane I 131
1

In one entry with another drug

Given together, or one or the other

Azedra
2

Studies by the year they started

13 studies that test it; most in 2014 (2)

Studies that test 3-Iodobenzylguanidine, by start year
YearStudies
20011
20051
20061
20071
20081
20111
20131
20142
20171
20191
20221
20231

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
4
Phase 2
8
Phase 3
1
Phase 4
1
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 3 · Other 11

David Bushnell (2) · Molecular Insight Pharmaceuticals, Inc. (2) · Nationwide Children's Hospital (1) · Masonic Cancer Center, University of Minnesota (1) · Cancer Research UK (1) · University of California, San Francisco (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1)

Often tested with

Tested in the same studies.

Cold Contaminant-free Iobenguane I-131 (2) · Edotreotide yttrium y-90 (1) · Fludarabine (1) · Thiotepa (1) · Rituximab (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test 3-Iodobenzylguanidine.

Studies

Open first, then newest update. How each study uses 3-Iodobenzylguanidine is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 14

Given beside what is tested · 2 — 3-Iodobenzylguanidine is usual care or a partner of the new treatment

Codes

What other systems call 3-Iodobenzylguanidine · ClinicalTrials.gg INT008719

  • MeSH (NLM) D0197973-IodobenzylguanidineConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 35MRW7B4ADIOBENGUANEConfirmed FDA, NLM
  • RxNorm 14448One source FDA

Also registered as iobenguane i-131 (UNII Q461L7AK4R · RxNorm 2053281).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.